Oramed Pharmaceuticals (ORMP)
NASDAQ:ORMP
Want to see ORMP full AI Analyst Report?
Total Valuation
Oramed Pharm has a market cap or net worth of $155.93M. The enterprise value is $150.04M.
Market Cap$155.93M
Enterprise Value$150.04M
Share Statistics
Oramed Pharm has 40,926,083 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding40,926,083
Owned by Insiders22.31%
Owned by Institutions22.41%
Financial Efficiency
Oramed Pharm’s return on equity (ROE) is 0.32 and return on invested capital (ROIC) is -6.05%.
Return on Equity (ROE)0.32
Return on Assets (ROA)0.28
Return on Invested Capital (ROIC)-6.05%
Return on Capital Employed (ROCE)-0.07
Revenue Per Employee153.85K
Profits Per Employee4.92M
Employee Count13
Asset Turnover<0.01
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Oramed Pharm is 1.4. Oramed Pharm’s PEG ratio is -0.00433.
PE Ratio1.4
PS Ratio59.00
PB Ratio0.59
Price to Fair Value0.59
Price to FCF-10.65
Price to Operating Cash Flow―
PEG Ratio-0.00433
Income Statement
In the last 12 months, Oramed Pharm had revenue of 2.00M and earned 64.05M in profits. Earnings per share was 1.53.
Revenue2.00M
Gross Profit13.00K
Operating Income-15.09M
Pretax Income75.32M
Net Income64.05M
EBITDA75.44M
Earnings Per Share (EPS)1.53
Cash Flow
In the last 12 months, operating cash flow was -9.54M and capital expenditures 194.68K, giving a free cash flow of -9.35M billion.
Operating Cash Flow-9.54M
Free Cash Flow-9.35M
Free Cash Flow per Share-0.23
Dividends & Yields
Oramed Pharm pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.57
52-Week Price Change79.31%
50-Day Moving Average3.89
200-Day Moving Average3.01
Relative Strength Index (RSI)41.44
Average Volume (3m)210.74K
Important Dates
Oramed Pharm upcoming earnings date is Jul 15, 2026, TBA (Confirmed).
Last Earnings DateJan 8, 2026
Next Earnings DateJul 15, 2026
Ex-Dividend Date―
Financial Position
Oramed Pharm as a current ratio of 6.98, with Debt / Equity ratio of ―
Current Ratio6.98
Quick Ratio6.98
Debt to Market Cap0.00
Net Debt to EBITDA-0.60
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Oramed Pharm has paid 11.31M in taxes.
Income Tax11.31M
Effective Tax Rate0.15
Enterprise Valuation
Oramed Pharm EV to EBITDA ratio is 0.97, with an EV/FCF ratio of -6.58.
EV to Sales36.44
EV to EBITDA0.97
EV to Free Cash Flow-6.58
EV to Operating Cash Flow-7.97
Balance Sheet
Oramed Pharm has $125.89M in cash and marketable securities with $761.00K in debt, giving a net cash position of $125.07M billion.
Cash & Marketable Securities$125.89M
Total Debt$761.00K
Net Cash$125.07M
Net Cash Per Share$3.06
Tangible Book Value Per Share$4.82
Margins
Gross margin is ―, with operating margin of -754.40%, and net profit margin of 3202.50%.
Gross Margin―
Operating Margin-754.40%
Pretax Margin3766.20%
Net Profit Margin3202.50%
EBITDA Margin3772.25%
EBIT Margin3766.20%
Analyst Forecast
The average price target for Oramed Pharm is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast-100.00%
EPS Growth Forecast―